Metraipolis › archive › dc_b2cfb7aba387
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials — Europe PMC PMID:41398053
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41398053
- DOI
- 10.1038/s41698-[numero omesso]-x
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T15:28:38.896Z
- SHA-256 of the archived text
20b291be1d439bbd7a2501327c5afe24cf8c5892c486af773ec309fdb2e9edd4- Stable URL of this page
https://metraipolis.com/documento/dc_b2cfb7aba387
How to cite
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials — Europe PMC PMID:41398053 — Europe PMC (en), https://europepmc.org/article/MED/41398053 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2cfb7aba387 (Metraipolis archive dc_b2cfb7aba387, sha256 20b291be1d439bbd7a2501327c5afe24cf8c5892c486af773ec309fdb2e9edd4)
BibTeX
@misc{dcb2cfb7aba387,
title = {Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials — Europe PMC PMID:41398053},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41398053},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2cfb7aba387; sha256 20b291be1d439bbd7a2501327c5afe24cf8c5892c486af773ec309fdb2e9edd4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41398053. Agents can read the archived copy with the MCP tool read_document.